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Mitochondrial DNA (MT-DNA) are intrinsically inflammatory nucleic acids released by damaged solid organs. Whether
circulating cell-free MT-DNA quantitation could be used to predict the risk of poor COVID-19 outcomes remains
undetermined.
We measured circulating MT-DNA levels in prospectively collected, cell-free plasma samples from 97 subjects with
COVID-19 at hospital presentation. Our primary outcome was mortality. Intensive care unit (ICU) admission, intubation,
vasopressor, and renal replacement therapy requirements were secondary outcomes. Multivariate regression analysis
determined whether MT-DNA levels were independent of other reported COVID-19 risk factors. Receiver operating
characteristic and area under the curve assessments were used to compare MT-DNA levels with established and
emerging inflammatory markers of COVID-19.
Circulating MT-DNA levels were highly elevated in patients who eventually died or required ICU admission, intubation,
vasopressor use, or renal replacement therapy. Multivariate regression revealed that high circulating MT-DNA was an
independent risk factor for these outcomes after adjusting for age, sex, and comorbidities. We also found that circulating
MT-DNA levels had a similar or superior area under the curve when compared against clinically established measures of
inflammation and emerging markers currently of interest as investigational targets for COVID-19 therapy.
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Introduction
Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) that has resulted in a global health emergency, causing consid-
erable strain on economic, social, and medical systems (1). COVID-19 presents in a wide spectrum of  
severity. Although most patients develop only mild or uncomplicated illness, others require prolonged 
hospitalization, ICU care, and intubation for respiratory support. In severe cases, patients can develop 
BACKGROUND. Mitochondrial DNA (MT-DNA) are intrinsically inflammatory nucleic acids released 
by damaged solid organs. Whether circulating cell-free MT-DNA quantitation could be used to 
predict the risk of poor COVID-19 outcomes remains undetermined.
METHODS. We measured circulating MT-DNA levels in prospectively collected, cell-free plasma 
samples from 97 subjects with COVID-19 at hospital presentation. Our primary outcome was 
mortality. Intensive care unit (ICU) admission, intubation, vasopressor, and renal replacement 
therapy requirements were secondary outcomes. Multivariate regression analysis determined 
whether MT-DNA levels were independent of other reported COVID-19 risk factors. Receiver 
operating characteristic and area under the curve assessments were used to compare MT-DNA 
levels with established and emerging inflammatory markers of COVID-19.
RESULTS. Circulating MT-DNA levels were highly elevated in patients who eventually died or 
required ICU admission, intubation, vasopressor use, or renal replacement therapy. Multivariate 
regression revealed that high circulating MT-DNA was an independent risk factor for these 
outcomes after adjusting for age, sex, and comorbidities. We also found that circulating MT-DNA 
levels had a similar or superior area under the curve when compared against clinically established 
measures of inflammation and emerging markers currently of interest as investigational targets for 
COVID-19 therapy.
CONCLUSION. These results show that high circulating MT-DNA levels are a potential early indicator 
for poor COVID-19 outcomes.
FUNDING. Washington University Institute of Clinical Translational Sciences COVID-19 Research 
Program and Washington University Institute of Clinical Translational Sciences (ICTS) NIH grant 
UL1TR002345.
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acute respiratory distress syndrome (ARDS), cytokine storm, multiorgan failure, and death (1). Although 
the underlying mechanisms of  severe COVID-19 illness remain unclear, it appears to be exacerbated by 
an overexuberant innate immune response (2). These observations have led to several ongoing clinical 
trials targeting components of  the innate immune response, such as inflammatory cytokine signaling and 
complement activation (3–5).
Previous work has established that viral infection can trigger cellular necrosis, which in turn inhibits 
viral replication along with amplifying antiviral immune responses through the release of  damage-associat-
ed molecular patterns (DAMPs) (6). DAMPs in particular are potent triggers of  innate responses through 
their engagement of  pattern recognition receptors, such as Toll-like receptors (TLRs), that drive the expres-
sion of  inflammatory cytokines and presentation of  viral antigens (7). Mitochondrial DNA (MT-DNA) 
is a member of  a group of  mitochondrial DAMPs (MT-DAMPs) released by injured or dying cells and is 
recognized by TLR9 because of  encoded hypomethylated CpG motifs reminiscent of  an ancestral bacte-
rial origin (8). MT-DNA levels have been previously shown to be elevated in the plasma of  patients who 
develop ARDS and multiorgan dysfunction during sepsis, as well as during sterile injury, including trauma, 
hemorrhagic shock, and ischemia/reperfusion (9–14). The release of  MT-DNA is often accompanied by 
the release of  other MT-DAMPs, such as N-formylated peptides, cytochrome c, and cardiolipin, which 
collectively engage multiple TLRs and the N-formylated peptide receptor-1 that in turn induce not only 
inflammatory cytokine expression (15–17) but also the generation of  reactive oxygen species and the facili-
tation of  neutrophil trafficking and activation (14, 18, 19). Through these effects, MT-DAMPs can directly 
contribute to acute lung injury and systemic inflammation (8). Given that ARDS secondary to SARS-
CoV-2 infection is also linked with lung tissue injury and immune cell activation (20), we asked if  elevated 
levels of  circulating MT-DNA could be used as a risk indicator for the development of  severe illness.
Here, we demonstrate that COVID-19 patients with high circulating levels of  cell-free MT-DNA at the 
time of  hospital presentation are more likely to require intensive care unit (ICU) care and intubation and 
are at heightened risk of  death. In addition, MT-DNA quantitation as predictor of  poor COVID-19 out-
comes is comparable to or better than inflammation indicators commonly used in current clinical practice, 
as well as certain emerging immune markers.
Results
Participants. A total of  107 subjects were assessed for eligibility from March 26, 2020, to April 26, 2020. 
Of  these, 97 adult subjects with laboratory-confirmed COVID-19 were included in our study (Table 1 and 
Figure 1). Ten subjects were excluded because they did not have samples from the day of  presentation. The 
median age of  the population in our study was 65 (interquartile range 54–73). Among these subjects, 55.7% 
(54/97) were male and 44.3% (43/97) were female; 77.3% (75/97) were African American, 20.6% (20/97) 
were White, 1% (1/97) was Middle Eastern, and 1% (1/97) was Indian; and 46.4% (45/97) were obese 
(BMI ≥ 30), while 49.5% (48/97) were nonobese (BMI 18.5–29.9) and 4.1% (4/97) were underweight (BMI 
< 18.5). A positive smoking history was reported in 46.4% (45/97) of  subjects. The median follow-up time 
was 81 days (interquartile range 74–87).
Comorbidities and outcomes. The primary outcome of  mortality was observed in 25.8% (25/97) of  
subjects in our study (Table 1). Those who died were older [76.2 versus 61.1 years, OR 1.08 (1.04–
1.13), P = 0.0003], were more likely to be smokers [64% versus 40.3%, OR 2.63 (1.04–7.00), P = 0.04], 
and were more likely to have type 2 diabetes mellitus [72% versus 45.8%, OR 3.04 (1.17–8.64), P = 
0.02], coronary artery disease [48% versus 19.4%, OR 3.8 (1.44–10.34), P = 0.007], and 2 or more 
comorbidities [84% versus 56.9%, OR 5.54 (1.72–24.91, P = 0.009] on univariate analysis (Table 1). 
The time to discharge for subjects who survived was mean 12.4 days, median 7 days (interquartile 
range 3–18), and range 1–56.
Of  the subjects with COVID-19, 56.7% (55/97, Table 2) required an ICU admission. These subjects 
were older [71 versus 54.4, OR 1.1 (1.06–1.15), P < 0.0001] and were more likely to have type 2 diabetes 
mellitus [65.5% versus 35.7%, OR 3.41 (1.49–8.07), P = 0.004] and 2 or more comorbidities [72.7% versus 
52.4%, OR 2.66 (1.14–6.38), P = 0.02]. As expected, the time to discharge was higher for patients requiring 
ICU admission [15 days (interquartile range 5–28), n = 27; versus 5 days (interquartile range 3–12.5), n = 
36, P = 0.0012]. Among patients, 25.8% (25/97) required invasive mechanical ventilation as a treatment 
for acute respiratory failure. The main clinical characteristic associated with higher risk for intubation was 
age, with a median of  70 years for intubated subjects compared with 61 years for nonintubated subjects 
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[OR 1.05 (1.01–1.09), P = 0.005] on univariate analysis (Table 3). As expected, the time to discharge was 
higher for patients who required intubation [27.5 days (interquartile range 18.5–38.5), n = 12; versus 5 days 
(interquartile range 3–13), n = 51, P < 0.0001].
COVID-19 patients with high circulating MT-DNA are at higher risk for mortality. To assess MT-DNA levels 
in COVID-19 patients, we utilized a previously established in situ quantitative PCR method (14) to measure 
the accumulation of  fragments derived from the mitochondrial encoded gene cytochrome b (MT-CYTB) 
within cell-free circulating plasma. Plasma MT-CYTB levels were elevated in those subjects who died from 
COVID-19 [7.56 (7.15–7.81, n = 25)] compared with those who survived [7.23 (7.050–7.485), n = 72, P 
= 0.008, Figure 2A] and were associated with an increased risk for mortality on univariate logistic regres-
sion (OR 2.24, 95% CI 1.29–4.16, P = 0.006). For MT-CYTB, area under the curve (AUC) for mortality 
was 0.68 (95% CI 0.54–0.81, Figure 2B). On multivariable logistic regression, plasma MT-CYTB levels 
remained an independent risk factor for mortality when adjusted for age, sex, and 2 or more comorbidities 
(ORadj, 2.19, 95% CI 1.19–4.28, P = 0.015, Table 4). Levels of  mitochondrial cytochrome c oxidase III 
(MT-COX3), another MT-DNA–encoded gene (Supplemental Figure 1B; supplemental material available 
online with this article; https://doi.org/10.1172/jci.insight.143299DS1), revealed an increased trend in 
subjects who died [5.63 (5.00–6.46), n = 25] relative to those who survived [5.32 (4.90–5.83), n = 72] but 
did not reach statistical significance (P = 0.1).
COVID-19 patients with high circulating MT-DNA are more likely to require ICU admission and intubation. 
Plasma MT-CYTB levels were elevated in those subjects with COVID-19 who required an ICU admis-
sion [7.52 (7.14–7.72), n = 55] compared with those who were not admitted to the ICU [7.13 (7.00–7.31), 
P < 0.0001, n = 42, Figure 3A]. MT-CYTB levels were associated with ICU admission on univariate 
logistic regression (OR 4.25, 95% CI 2.15–9.59, P = 0.0001). For MT-CYTB, AUC for ICU admission 
was 0.75 (95% CI 0.65–0.85, Figure 3B). On multivariable logistic regression, plasma MT-CYTB levels 
remained an independent risk factor for ICU admission after adjusting for age, sex, and 2 or more comor-
bidities (ORadj, 3.97, 95% CI 1.83–10.34, P = 0.002, Table 5). Notably, we also made similar findings 
for MT-COX3 [Supplemental Figure 1C; ORadj for age, sex, and 2 or more comorbidities, 1.47; 95% CI 
1.14–1.95; P = 0.005; AUC of  COX3 for ICU admission 0.69 (95% CI 0.58–0.79)].
Table 1. Demographic and clinical characteristics associated with mortality
Total (n = 97) Alive (n = 72) Deceased (n = 25) OR for mortality (95% CI) P value
Demographics
Age, yA 65 (54–73) 61.1 (50.3–70.5) 76.2 (65.3–84.9) 1.08 (1.04–1.13) 0.0003
Male n (%)B 54 (55.6) 39 (54.17) 15 (60) 1.26 (0.5–3.27) 0.6
Female n (%)B 43 (44.3) 33 (45.83) 10 (40)
African AmericanB 75 (77.3) 57 (79.2) 18 (72) 0.6 (0.24–2) 0.4
BMIA 29.1 (24.7–34.4) 28.9 (24.7–33.3) 30.9 (24.5–37.6) 1.02 (0.96–1.08) 0.4
Smoking historyB 45 (46.3) 29 (40.3) 16 (64) 2.63 (1.04–7) 0.04
Comorbidities
HTNB 73 (75.2) 51 (70.8) 22 (88) 3.02 (0.91–13.71) 0.09
DMIIB 51 (52.5) 33 (45.8) 18 (72) 3.04 (1.17–8.64) 0.02
COPDB 13 (14.4) 7 (9.7) 6 (24) 2.93 (0.85–9.89) 0.08
CKD > 2B 37 (38.1) 24 (33.3) 13 (52) 2.16 (0.85–5.53) 0.1
ESRDB 8 (8.2) 4 (5.6) 4 (16) 3.23 (0.71–14.80) 0.1
CADB 26 (26.8) 14 (19.4) 12 (48) 3.8 (1.44–10.34) 0.007
CVAB 21 (21.6) 14 (19.4) 7 (28) 1.61 (0.54–4.53) 0.3
VTEB 16 (16.4) 14 (19.4) 2 (8) 0.36 (0.05–1.42) 0.2
Two or more comorbiditiesB 62 (63.9) 41 (56.9) 21 (84) 5.54 (1.72–24.91) 0.009
Three or more comorbiditiesB 50 (51.5) 32 (43.8) 18 (75) 3.21 (1.23–9.15) 0.02
Continuous variables are reported as median (interquartile range). P values indicate differences between alive and deceased COVID-19 patients. Races of 
participants: 77.3% were African American, 20.6% were White, 1% was Middle Eastern, and 1% was Indian. AValues presented as median and interquartile 
range. BValues presented as number and percentage of the column total. HTN, hypertension; DMII, diabetes mellitus type 2; COPD, chronic obstructive 
pulmonary disease; CKD > 2, chronic kidney disease; ESRD, end-stage renal disease; CAD, coronary artery disease; CVA, cerebrovascular accident; VTE, 
venous thromboembolism.
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Additionally, plasma MT-CYTB levels were elevated in those subjects with COVID-19 who 
required intubation [7.69 (7.54–8.07, n = 25)] versus those who did not require intubation [7.18 
(7.033–7.438), n = 72, P < 0.0001, Figure 3C]. Plasma MT-CYTB levels were associated with intuba-
tion on univariate logistic regression (OR 9.12, 95% 3.77–28.56, P < 0.0001). For MT-CYTB, AUC 
for intubation was 0.86 (95% CI 0.76–0.95, Figure 3D). On multivariable logistic regression, plasma 
MT-CYTB levels remained an independent risk factor for intubation (ORadj, 8.47, 95% CI 3.49–27.33, 
P < 0.0001, Table 6). Similar findings were observed with MT-COX3 [Supplemental Figure 1D; ORadj 
for age, sex, and 2 or more comorbidities, 2.69; 95% CI 1.77–4.74; P < 0.0001; AUC for intubation 
0.80 (95% CI 0.69–0.91)].
COVID-19 patients with high circulating MT-DNA are more likely to require vasopressors and renal replace-
ment therapy. Plasma MT-CYTB levels were also elevated in those subjects with COVID-19 who 
ultimately had end organ dysfunction requiring vasopressors [7.63 (7.35–8.02), n = 29] compared 
with those who did not require vasopressors [7.20 (7.04–7.43), P < 0.0001, n = 68, Figure 4A]. For 
MT-CYTB, AUC for vasopressor requirement was 0.80 (95% CI 0.69–0.91, Figure 4B). Similarly, plas-
ma MT-COX3 levels were elevated in subjects requiring vasopressors [5.98 (5.25–6.68), n = 29; com-
pared with 5.25 (4.85–5.70), P = 0.0001, n = 68 (Supplemental Figure 1E); AUC of  COX3 for vaso-
pressor requirement was 0.74 (95% CI 0.62–0.86)]. Notably, plasma MT-CYTB levels on admission 
were also elevated in subjects who had end organ dysfunction requiring RRT while in the ICU [7.75 
(7.64–8.08), n = 14] compared with those who did not require RRT [7.2 (7.04–7.47), P < 0.0001, n = 
81, Figure 4C]. For MT-CYTB, AUC for RRT requirement was 0.95 (95% CI 0.91–0.99, Figure 4D). 
Similarly, plasma MT-COX3 levels were elevated in subjects who required RRT [6.59 (6.36–7.12), n = 
14] compared with those who did not require RRT [5.24 (4.81–5.69), P < 0.0001, n = 81] (Supplemen-
tal Figure 1F); AUC of  COX3 for RRT requirement was 0.94 (95% CI 0.88–0.99)].
Circulating MT-DNA levels show similar or improved sensitivity over clinically established measurements of  
inflammation used in COVID-19 patients. Plasma MT-CYTB levels had a similar AUC for mortality when 
compared with lactic acid dehydrogenase (LDH), ferritin, or D-dimer levels and were better than C-reactive 
protein (CRP) drawn within the first 24 hours of  presentation (Figure 5A). Importantly, the AUC for plas-
ma MT-CYTB levels was superior to CRP, LDH, ferritin, and D-dimer levels when predicting the need for 
an ICU admission (Figure 5B) or intubation (Figure 5C). A similar pattern was identified for MT-COX3 
when compared with CRP, LDH, ferritin, and D-dimer levels for predicting the need for an ICU admission 
(Supplemental Figure 2B) and inferior for predicting mortality (Supplemental Figure 2A) but was superior 
to these clinically utilized markers for the need for intubation (Supplemental Figure 2C).
Circulating MT-DNA levels correlate with other emerging markers of  COVID-19 severity. Plasma MT-CYTB 
levels moderately correlated with concurrently measured levels of  IL-6, which has been implicated 
in the pathogenesis of  COVID-19 (r = 0.39, 95% CI 0.196–0.555, P = 0.0001, n = 92, Figure 6A). 
Figure 1. CONSORT flow diagram showing enrollment of patients, allocation, and outcomes. RRT, renal replace-
ment therapy.
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Similarly, MT-CYTB levels highly correlated with plasma soluble C5b-9, which is a marker of  com-
plement activation and suggests the formation of  a membrane attack complex (MAC) (r = 0.49, 95% 
CI 0.32–0.64, P < 0.0001, n = 95, Figure 6B). MT-CYTB also correlated with the neutrophil-to-lym-
phocyte ratio (r = 0.37, 95% CI 0.17–0.54, P = 0.0003, n = 90, Figure 6C). Plasma MT-CYTB levels 
had a similar or improved accuracy compared with IL-6 for mortality (Supplemental Figure 3A), ICU 
admission (Supplemental Figure 3B), and intubation (Supplemental Figure 3C).
We also observed significant correlations with other biomarkers that have been implicated in the patho-
genesis of  COVID-19, such as CXCL9 (r = 0.31, 95% CI 0.11–0.49, P = 0.002, n = 93, Figure 6D), CCL2 
(r = 0.25, 95% CI 0.05–0.44, P = 0.01, n = 93, Figure 6E), CXCL10 (r = 0.25, 95% CI 0.05–0.44, P = 0.01, 
P = 94, Figure 6F), IL-1RA (r = 0.43, 95% CI 0.25–0.59, P < 0.0001, n = 94, Figure 6G), and IL-2R (r = 
0.27, 95% CI 0.07– 0.46, P = 0.007, P = 93, Figure 6H). Similarly, the levels of  HGF highly correlated with 
MT-CYTB in COVID-19 (r = 0.47, 95% CI 0.29–0.62, P < 0.0001, n = 94, Figure 6I).
Discussion
Here we observe that high levels of  circulating MT-DNA are an early independent risk factor for severe illness 
and mortality in hospitalized patients with COVID-19, after adjusting for age, sex, and comorbidities. Impor-
tantly, we made similar findings for 2 MT-DNA genes, MT-CYTB and MT-COX3, although the latter target 
did not reach significance for mortality risk. The reasons for this incongruence are not clear. One possibility is 
the accumulation of  heteroplasmic mitochondrial genome deletions or point mutations that could prevent or 
attenuate PCR primer recognition (21). Heteroplasmic DNA deletions have been repeatedly demonstrated to 
accumulate with age within the MT-COX3 gene (22–24), and to a lesser degree, within the MT-CYTB locus, 
due to age-related defects of  mitochondrial DNA polymerase proofreading capability (25, 26).
Although our studies were not specifically designed to identify the mechanisms that drive peripheral blood 
MT-DNA accumulation, significant correlations between LDH and IL-6 with MT-DNA levels point to a poten-
tial deleterious role for cellular necrosis in COVID-19 pathophysiology. LDH release and IL-6 production are 
reported indicators of cellular necrosis (27, 28). A specific form of necrosis, necroptosis, has been demonstrated 
to induce the release of damaged mitochondria (29). Necroptosis is characterized by the eventual loss of plasma 
membrane integrity due to the kinase activity of the receptor-interacting proteins 1 (RIPK1) and RIPK3 (30) 
Table 2. Demographic and clinical characteristics associated with ICU admission
No ICU (n = 42) ICU (n = 55) OR for ICU (95% CI) P value
Demographics
Age, yA 54.4 (38.5–64.2) 71 (63.8–78.9) 1.1 (1.06–1.15) <0.0001
Male n (%)B 19 (45.2) 35 (63.6) 2.11 (0.93–4.86) 0.07
Female n (%)B 23 (54.76) 20 (36.36)
African AmericanB 33 (78.6) 42 (76.4) 0.88 (0.32–2.29) 0.8
BMIA 30.2 (25.3–34.8) 28.4 (24.4–33) 0.98 (0.92–1.03) 0.5
Smoking historyB 15 (35.7) 30 (54.5) 2.16 (0.95–5) 0.067
Comorbidities
HTNB 29 (69) 44 (80) 1.79 (0.7–4.61) 0.2
DMIIB 15 (35.7) 36 (65.5) 3.41 (1.49–8.07) 0.004
COPDB 6 (14.3) 7 (12.7) 0.87 (0.26–2.93) 0.8
CKD > 2B 12 (28.6) 25 (45.5) 2.08 (0.89–5) 0.09
ESRDB 4 (9.5) 4 (7.3) 0.74 (0.16–3.33) 0.7
CADB 8 (19.1) 18 (32.7) 2.06 (0.81–5.61) 0.1
CVAB 7 (16.7) 14 (25.5) 1.7 (0.63–4.94) 0.3
VTEB 8 (19.1) 8 (14.6) 0.72 (0.24–2.15) 0.5
Two or more comorbiditiesB 22 (52.4) 40 (72.7) 2.66 (1.14–6.38) 0.02
Three or more comorbiditiesB 16 (38.1) 34 (61.8) 2.63 (1.16–6.11) 0.02
Continuous variables are reported as median (interquartile range). P values indicate differences between not ICU and ICU admitted COVID-19 patients. Data 
not available for non–African American participants. AValues presented as median and interquartile range. BValues presented as number and percentage of 
the column total. HTN, hypertension; DMII, diabetes mellitus type 2; COPD, chronic obstructive pulmonary disease; CKD > 2, chronic kidney disease; ESRD, 
end-stage renal disease; CAD, coronary artery disease; CVA, cerebrovascular accident; VTE, venous thromboembolism.
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and has been reported to act as a host defense mechanism when apoptotic death pathways are disabled by viral 
infection (31). For example, in a mouse model of influenza infection, necroptosis was shown to inhibit viral 
replication but with deleterious consequences to bronchial epithelial integrity (32). In humans, both H5N1 and 
H1N1 influenza–induced ARDS have been shown to be associated with necrotic cell death within the distal 
pulmonary epithelia (33, 34). Intriguingly, the accessory protein open reading frame 3a (Orf3a) expressed within 
the highly related SARS-CoV-1 genome has been recently demonstrated to induce necroptosis through activat-
ing RIPK3 (35). SARS-CoV-2 also expresses an Orf3a accessory protein (36). However, whether SARS-CoV-2 
Orf3a promotes necroptosis has yet to be determined. Some MT-DNA release may also result from innate 
immune cell activation. For example, human neutrophils following activation extrude their MT-DNA due to 
an inability to complete mitophagy (37). Additionally, neutrophil extracellular traps (NETs), which have been 
found in the peripheral circulation of COVID-19 patients (38), are rich in MT-DNA (39). Neutrophils have also 
been identified as undergoing metabolic reprogramming in the context of SARS-CoV-2 (40). In addition to neu-
trophils, activated platelets also release mitochondria (41), which in turn can induce NET generation, possibly 
contributing to pulmonary prothrombotic complications observed in patients with severe COVID-19 illness (42). 
Additionally, MT-DNA has been shown to directly promote NETosis (43, 44). The source and mechanisms of  
MT-DNA release in response to SARS-CoV-2 infection are the subject of future investigation.
Multiple clinically established biomarkers, such as LDH, ferritin, CRP, and D-dimer, are currently 
being evaluated to assess the risk of  clinical deterioration from a COVID-19 diagnosis (40, 45–49). How-
ever, as products of  gene expression in response to both acute and chronic stimuli, they tend to be largely 
nonspecific measures of  systemic inflammation, with the exception of  LDH, a marker of  cell death. Nev-
ertheless, LDH can also be released by cells undergoing apoptosis, a predominantly antiinflammatory form 
of  cell death (50). Ferritin is primarily produced by the liver and serves as an acute phase reactant. Similar-
ly, D-dimer is a nonspecific test and provides us minimal insight into the underlying pathophysiology of  the 
disease or events occurring at the cellular level. In contrast, there are accumulating observations that high 
amounts of  MT-DNA release are specifically generated by necrotic cells (51). Additionally, high MT-DNA 
levels have been shown to be associated with acute lung injury, in multiple independent cohorts (12, 13, 52). 
In our cohort, although CYTB performed similarly to ferritin/D-dimer for mortality, it performed better 
than these markers in the context of  identifying those at risk for an ICU admission or intubation, which 
Table 3. Demographic and clinical characteristics associated with intubation
Not intubated (n = 72) Intubated (n = 25) OR for intubation (95% CI) P value
Demographics
Age, yA 61 (50.35–71.9) 69.8 (63.9–78.5) 1.05 (1.01–1.09) 0.005
Male n (%)B 38 (52.8) 16 (64) 1.59 (0.63–4.19) 0.3
Female n (%)B 34 (47.22) 9 (36)
African AmericanB 56 (77.8) 19 (76) 0.9 (0.31–2.81) 0.8
BMIA 28.9 (24.4–34.8) 29.7 (25–32.9) 1.0 (0.94–1.06) 0.9
Smoking historyB 32 (44.5) 13 (52) 1.35 (0.54–3.4) 0.5
Comorbidities
HTNB 53 (73.6) 20 (80) 1.43 (0.49–4.70) 0.5
DMIIB 36 (50) 15 (60) 1.5 (0.6–3.87) 0.4
COPDB 8 (11.1) 5 (20) 2.0 (0.55–6.71) 0.3
CKD > 2B 25 (34.7) 12 (48) 1.73 (0.68–4.39) 0.2
ESRDB 5 (6.9) 3 (12) 1.82 (0.35–8.07) 0.4
CADB 17 (23.6) 9 (36) 1.82 (0.66–4.82) 0.2
CVAB 14 (19.4) 7 (28) 1.61 (0.54–4.53) 0.4
VTEB 13 (18) 3 (12) 0.61 (0.13–2.14) 0.5
Two or more comorbiditiesB 44 (61.1) 18 (72) 2.01 (0.74–6.08) 0.2
Three or more comorbiditiesB 34 (47.2) 16 (64) 1.98 (0.79–5.25) 0.2
Continuous variables are reported as median (interquartile range). P values indicate differences between not intubated and intubated COVID-19 patients. 
Data not available for non–African American participants. AValues presented as median and interquartile range. BValues presented as number and 
percentage of the column total. HTN, hypertension; DMII, diabetes mellitus type 2; COPD, chronic obstructive pulmonary disease; CKD > 2, chronic kidney 
disease; ESRD, end-stage renal disease; CAD, coronary artery disease; CVA, cerebrovascular accident; VTE, venous thromboembolism.
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are important resource utilization metrics. Moreover, we observed that MT-DNA levels were approximate-
ly 5-fold higher in COVID-19 patients who developed severe pulmonary dysfunction or eventually died, 
suggesting it is at least as sensitive a biomarker as other clinically established and exploratory indicators 
used in prediction models. To conduct plasma MT-DNA measurements, we employed a rapid PCR assay 
technique that takes about 60 minutes to complete because of  the elimination of  the DNA purification 
step. In resource-limited settings, this can be especially important given the current necessity to identify 
subjects at a higher risk of  clinical deterioration. Additionally, PCR-based assays measuring MT-DNA tend 
to be less cost prohibitive and do not need specialized equipment, facilitating easy implementation. For 
the abovementioned reasons, we suggest that MT-DNA be investigated as an adjunct clinical biomarker 
in COVID-19. Nevertheless, whether MT-DNA levels are equivalent or better measures than routinely 
obtained laboratory measurements will require additional validation with independent cohorts.
Based on our data from this study, it is not possible to clearly determine if  circulating MT-DNA contrib-
utes to the pathogenesis of  COVID-19. Nevertheless, cell-free MT-DNA is itself  a signatory marker for the 
release of  other MT-DAMPs, which collectively drive proinflammatory cytokine expression through the 
engagement of  pattern recognition receptors on innate immune cells (7). MT-DAMPs drive IL-6 expression 
by macrophages (29) and stimulate IL-8 release by neutrophils (9). Notably, IL-6 suppresses lymphopoie-
sis (53) while IL-8 promotes neutrophil release from the bone marrow (54) and, therefore, could possibly 
explain our observed correlation between MT-DNA levels and elevations in the neutrophil-to-lymphocyte 
ratio. We additionally noted a significant correlation between MAC and MT-DNA levels. Extracellular 
mitochondria have been reported to activate complement. Mannose-binding lectin has been observed to 
bind to cell-free mitochondria, resulting in C3 consumption in the peripheral blood of  mice (55). There-
fore, it is interesting to note that C3 consumption is a general sign of  C3 convertase activity, which would 
Figure 2. High circulating MT-DNA levels predict a higher risk of mortality in COVID-19 patients. Plasma for 
determination of circulating levels of MT-CYTB was obtained at time of hospital presentation. (A) Box-and-whisker 
plots of MT-CYB levels in relation to mortality status in COVID-19 patients. The box plots depict the minimum and 
maximum values (whiskers), the upper and lower quartiles, and the median. The length of the box represents the 
interquartile range. (B) Receiver operating characteristic (ROC) curves in predicting the outcome mortality based on 
MT-CYTB levels. Statistical significance was determined using Mann-Whitney U test (**P < 0.01).
Table 4. Multivariate analysis associated with mortality
Adjusted OR for mortality (95% CI) P value
MT-CYTB 2.24 (1.28–4.16) 0.015
Age 1.074 (1.026–1.131) 0.003
Sex (male) 1.380 (0.460–4.362) 0.570
Two or more comorbidities 2.578 (0.611–14.200) 0.225
N = 97 (25 mortality events).
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be a prerequisite for the downstream generation of  membrane attack components (56). Along those lines, 
complement activation has been implicated in the pathogenesis of  COVID-19–related end organ damage, 
including acute lung injury (57, 58), with potential therapeutic implications (5, 59). Finally, MT-DAMPs, 
unlike other inflammatory markers linked to poor outcomes of  COVID-19 patients, have been reported 
to directly cause acute pulmonary dysfunction and tissue damage (60). Administration of  MT-DAMPs 
into the bloodstream or pulmonary airways of  rodents promotes acute lung injury mediated by neutrophil 
chemotaxis and reactive oxygen species generation to mitochondrial formylated peptides (9, 14). In these 
studies, the formylated peptide receptor-1 inhibitor cyclosporine H was shown to inhibit MT-DAMP–medi-
ated acute lung injury. Given ongoing clinical trials that target the effects of  IL-6, complement activation 
and NETs in COVID-19 patients (3–5, 61, 62) future approaches that block necroptosis or MT-DAMP 
recognition could also be warranted.
Our study has several limitations. First, we were unable to concurrently enroll a COVID-19–nega-
tive group with severe respiratory disease. Our center, like many others, experienced a sharp decline in 
hospital presentations for illnesses other than COVID-19, making it difficult to collect samples for an 
adequately matched control group. Additionally, as our samples were drawn as a part of  a prospective 
study of  SARS-CoV-2 PCR-positive patients, any other adequately matched control group would not 
be entirely comparable, as not drawn concurrently. However, it is unlikely that MT-DNA levels are 
considerably different between patients with COVID-19 and acute respiratory diseases arising from 
Figure 3. High circulating MT-DNA levels predict a higher risk of ICU requirement and intubation in COVID-19 
patients. Plasma for determination of circulating levels of MT-CYTB was obtained at time of hospital presentation. 
Box-and-whisker plots of MT-CYB levels in relation to (A) ICU admission and (C) intubation in COVID-19 patients. The 
box plots depict the minimum and maximum values (whiskers), the upper and lower quartiles, and the median. The 
length of the box represents the interquartile range. Empty dots indicate alive patients and shaded dots indicate 
deceased patients. ROC curves in predicting the outcome (B) ICU and (D) intubation based on MT-CYTB levels. Statisti-
cal significance was determined using Mann-Whitney U test (****P <.0001).
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other etiologies. For example, reports have shown that increased MT-DNA levels in critically ill patients 
are significantly associated with a higher risk of  developing ARDS regardless of  the underlying etiol-
ogy (12, 13, 52). Nakahira et al. also showed that high level of  plasma MT-DNA is a general marker 
of  mortality risk in ICU patients (13). Additionally, more recent work from Huang et al. (52) shows 
that high plasma MT-DNA levels in ARDS patients are associated with increased risk for mortality 
regardless of  admission diagnosis. Indeed, several emerging studies suggest that biomarkers may be 
no different in subjects with COVID-19–induced lung injury versus lung injury due to other etiologies 
(63). However, the strength of  our study lies in an assay that can potentially identify subjects present-
ing with COVID-19 who are likely to develop adverse outcomes during their hospitalization, which 
becomes increasingly important when resources are constrained as has been unfortunately too common 
during this pandemic (64–66). Second, this study does not assess how MT-DNA correlates with viral 
load in COVID-19, which is especially important in the context of  deciding when to intervene with 
targeted therapeutics (67–69). Therefore, further studies will be necessary to evaluate whether it may be 
a predictor of  response to treatment (70). Third, decision-making in the ICU changed over the course 
of  our enrollment. For example, there was a tendency toward intubating earlier in the course of  the 
critical illness in the initial months of  the COVID-19 pandemic. We also lack data to support objective 
measurement of  disease severity at the time of  presentation as can be reflected in SOFA, APACHE, or 
CURB65 scores. However, we identified MT-DNA levels as a predictor of  severity utilizing mortality 
as a primary endpoint, then requirement of  ICU admission and requirement for intubation as indepen-
dent secondary endpoints. Additionally, we identified MT-DNA levels as a predictor of  disease severity 
utilizing requirement of  vasopressors and RRT while in the ICU as independent secondary endpoints 
of  end organ dysfunction.
It also remains possible that our findings may not generally apply to all patients who contract 
COVID-19. Members of  underrepresented minority communities are at significantly higher risk for 
COVID-19 infection as well as suffering its most severe outcomes. Our analysis was conducted in an 
urban medical center that serves a large African American community who may have a tendency to 
inherit MT-DNA variations that differ from other groups. This may be most exemplified in a recent 
report that shows certain point mutations within the MT-DNA of  aging African Americans are asso-
ciated with decreased pulmonary maximal inspiratory pressures (MIPs) (71). However, this study also 
found other point MT-DNA mutations in African Americans were associated with increased MIPs, 
suggesting a more complex picture for MT-DNA variation and its link to respiratory function. Nev-
ertheless, this MT-DNA variation was not within the primer target sequences used in our assays. 
Finally, prior studies that analyzed other diseases that involve respiratory distress, such as ARDS and 
Table 5. Multivariate analysis associated with ICU admission
Adjusted OR for ICU admission (95% CI) P value
MT-CYTB 3.97 (1.83–10.34) 0.002
Age 1.113 (1.062–1.180) <0.0001
Sex (male) 2.060 (0.688–6.478) 0.201
Two or more comorbidities 0.465 (0.113–1.713) 0.264
N = 97 (55 ICU events).
Table 6. Multivariate analysis associated with intubation
Adjusted OR for intubation (95% CI) P value
MT-CYTB 8.48 (3.48–27.33) <0.0001
Age 1.059 (1.008–1.119) 0.03
Sex (male) 1.339 (0.381–4.920) 0.649
Two or more comorbidities 0.831 (0.166–4.368) 0.821
N = 97 (25 intubation events). 
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primary lung allograft dysfunction, on populations predominantly composed of  Caucasians, and to 
lesser extent, underrepresented minority groups, demonstrated significant associations with cell-free 
circulating MT-DNA (12–14). Taken together with our findings, these reports support a robust asso-
ciation with MT-DNA levels and poor outcomes from COVID-19 infection that is likely applicable to 
all racial groups.
In summary, we demonstrate that MT-DNA measured early in the disease course can predict 
survival status, requirement for ICU-level care, the need for endotracheal intubation, as well as end 
organ dysfunction requiring vasopressors and RRT. We also show that MT-DNA levels are associated 
with exploratory biomarkers implicated in the pathogenesis of  COVID-19–related morbidity and mor-
tality. Further studies will be needed to discern the contribution of  MT-DAMPs such as MT-DNA to 
COVID-19 pathogenesis, as well as to understand whether MT-DNA and other inflammatory media-
tors, such as activated complement, work synergistically to promote cellular injury.
Methods
Study design, settings, and participants. This prospective cohort study utilized cell-free plasma samples 
that had been prospectively collected from 97 adult patients with confirmed COVID-19 presenting to 
the Barnes-Jewish Hospital from March 15, 2020, to April 24, 2020. Eligible participants included 
Figure 4. High circulating MT-DNA levels predict a higher risk for end organ dysfunction requiring vasopressors 
and renal replacement in COVID-19 patients. Plasma for determination of circulating levels of MT-CYTB was 
obtained at time of hospital presentation. Box-and-whisker plots of MT-CYB levels in relation to (A) require-
ment for vasopressors and (C) renal replacement in COVID-19 patients. The box plots depict the minimum and 
maximum values (whiskers), the upper and lower quartiles, and the median. The length of the box represents the 
interquartile range. ROC curves in predicting the outcomes (B) requirement for pressors and (D) renal replacement 
based on MT-CYTB levels. Statistical significance was determined using Mann-Whitney U test (****P < 0.0001).
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consented adults, greater than 18 years old, presenting with COVID-19 symptoms who received a 
COVID-19 test at the time of  hospital presentation that resulted in a COVID-19 diagnosis. Diag-
nosis of  COVID-19 was based on a positive nasopharyngeal swab test. Excluded participants were 
COVID-19–diagnosed patients who did not have plasma samples collected within 24 hours of  time of  
hospital presentation.
Outcome definition. Subjects were followed through June 29, 2020. The primary outcome was mortality. 
The secondary outcomes included (a) the need for an ICU admission and (b) endotracheal intubation, as 
well as the development of  end organ dysfunction while in the ICU requiring (c) vasopressors and (d) RRT. 
Subjects who were on dialysis prior to admission were excluded from the RRT outcome analysis. These 
outcomes were abstracted utilizing an honest broker system from electronic medical records.
Figure 5. Circulating MT-DNA levels have similar or improved accuracy over clinically utilized biomarkers for outcomes of severity in COVID-19. 
Blood samples for determination of biomarkers levels were collected within 24 hours from hospital presentation. ROC curves in predicting the 
outcomes (A) mortality, (B) admission to ICU, and (C) intubation based on MT-CYTB (red), reactive C protein (CRP) (blue), ferritin (black), lactic 
acid dehydrogenase (LDH) (purple), and D-dimer (green) levels. AUC with 95% CI and P values for the different biomarkers are summarized in the 
corresponding tables.
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Sample collection and processing. MT-DNA and other cytokines were measured in cell-free plasma of  
subjects within the first 24 hours of  emergency department presentation. Blood samples were collected in 
EDTA-containing vacutainers (BD Biosciences) and subjected to 2 rounds of  centrifugation to generate 
platelet poor plasma, first at 2500g for 20 minutes to generate plasma. The plasma was removed from 
vacutainers and centrifuged at 13,000g in sterile nuclease-free eppendorf  tubes (Thermo Fisher Scientific) 
for 10 minutes to remove platelets. These platelet-poor specimens were then immediately stored at −80°C 
Figure 6. Circulating MT-DNA levels correlate with other emerging markers of inflammation and cytokines in COVID-19 patients. Scatter plots showing 
the correlation between MT-CYTB and (A) IL-6, (B) C5b-9 (terminal complement complex), and (C) neutrophil-to-lymphocyte ratio (NLR), (D) CXCL9, (E) 
CCL2, (F) CXCL10, (G) IL-1RA, (H) IL-2R, and (I) HGF. The degree of correlation was assessed using Spearman’s rank correlation coefficient test.
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until further analysis. Concurrently measured clinical markers (i.e., CRP, ferritin, lactate dehydrogenase, 
D-dimer) were obtained from the electronic medical record.
MT-DNA quantification. MT-DNA quantification real-time PCR was performed in a Bio-Rad 
CFX-Connect machine using reaction mixture containing 0.1 μL of  cell-free plasma, 10 μL iQ SYBR 
Green Supermix (Bio-Rad), 0.5 μL of  5 μM forward and reverse primers, and 8.9 μL H2O. Assays were 
performed in triplicate under the following conditions: 1 cycle at 95°C for 3 minutes, then up to 40 cycles 
at 95°C for 10 seconds and 55°C for 30 seconds, and then a melt curve was performed from 65°C to 95°C 
(0.5°C every 5 seconds). Primers for human cytochrome b (CYB; forward 5′-ATGACCCCAATAC-
GCAAAAT-3′ and reverse 5′-CGAAGTTTCATCATGCGGAG-3′) and human cytochrome c oxi-
dase subunit III (COX3: forward 5′-ATGACCCACCAATCACATGC-3′ and reverse 5′-ATCACAT-
GGCTAGGCCGGAG-3′) were synthesized by Integrated DNA Technologies. Copy number was 
estimated by comparison to a real-time PCR standard amplification curve. To generate the standard 
curve, selected regions of  human purified MT-DNA containing the target sequences for MT-CYTB (for-
ward 5′-ATGACCCCAATACGCAAAAT-3′ and reverse 5′-GACGGATCGGAGAATTGTGT-3′) and 
MT-COX3 (forward 5′-ATGACCCACCAATCACATGC-3′ and reverse 5′-ATCAATAGATGGAGA-
CATAC-3′) were amplified by PCR under the following conditions: initial denaturation at 94°C for 2 
minutes, then up to 35 cycles of  denaturation at 94°C for 30 seconds, annealing at 50°C for 30 seconds, 
and extension at 72°C for 1 minute. After amplification, MT-DNA was gel purified, extracted, and 
quantified by NanoDrop (Thermo Fisher Scientific). Serial dilutions were then used to calibrate the 
real-time PCR standard curves. Final results were expressed as copy number of  MT-DNA, and their 
absolute values were converted to log10 before statistical analysis.
Quantification of  cytokines and complement activation. Cell-free plasma was analyzed using a Cytokine 
35-Plex Human Panel, which provides simultaneous measurement of  35 cytokines (Thermo Fisher 
Scientific). The assay was performed in accordance with manufacturer’s instructions with each subject 
sample performed in duplicate and then analyzed on a Luminex FLEXMAP 3D instrument. Internal 
validation control with every plate also was run in duplicate. Complement activation was assessed 
in cell-free plasma specimens (not previously thawed) using the soluble C5b-9 assay (BD Biosciences 
OptEIA Human C5b-9 ELISA set).
Statistics. Continuous variables were reported as median (interquartile range). The predictive value of  
each biomarker was expressed as AUC derived from the relative ROC curve. Spearman r coefficient was 
calculated to estimate the correlation between 2 continuous variables. Univariate logistic regression anal-
ysis was used to calculate the unadjusted ORs. Independent variables known to have a biological rela-
tionship with the outcomes were selected a priori based on existing literature for the multivariate logistic 
model to calculate the adjusted ORs (72–74). Model diagnostics were performed with Corrected Akaike 
Information Criterion, log likelihood, and model deviance. The MT-DNA was log (base 10) transformed 
prior to data analysis to better meet model assumptions. To facilitate interpretation for this variable, the 
OR estimates were raised to the 0.5 power, which is interpreted as the increase in the odds of  the outcome 
for each 0.5 change in MT-DNA on the log scale. All the statistical analyses were calculated and all figures 
were prepared using GraphPad Prism 8.4.2 (GraphPad Software Inc.). For all the analyses, a P value less 
than 0.05 was considered significant.
Study approval. The study was approved by the Washington University School of  Medicine Institutional 
Review Board (ID 202004091 and 202003085). Written informed consent was obtained from all subjects.
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